Why the study?
Does growth hormone replacement therapy improve clinical and cardiovascular outcomes in adults with growth hormone deficiency?
Does growth hormone replacement therapy improve clinical and cardiovascular outcomes in adults with growth hormone deficiency?
Growth hormone replacement therapy, when properly diagnosed and titrated, improves cardiovascular risk profiles, body composition, and mortality in adults with GH deficiency.
Answers are grounded in this paper and cite their sources.
May support GH replacement in deficient adults; leaves open confirmatory RCTs on CV outcomes and mortality.
Adult growth hormone (GH) deficiency is associated with insulin resistance, elevated cardiovascular risk profile, increased fat mass, reduced muscle mass, skeletal fragility, and impaired quality of life. GH replacement therapy improves body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life, while reducing mortality. Prior to initiation of GH replacement therapy, it is essential to diagnose GH deficiency via a GH stimulation test in adults suspicious of such deficiency. Therapy should be started using (individualized) low dose of GH, followed by titration to the normal range of insulin-like growth factor-1. Clinical improvements should be monitored and side effects should be minimized.
No takes yet. Share an insight, caveat, or question.
Jung Hee Kim (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: